Payment overview · 2025
General Payments
$667.80
26 reported records · 7 companies
Healthcare provider profile · identity verified
David S Lilienthal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLAIRTON, PA · NPI 1598730921
Verified facts
What the public records show
CMS Open Payments records show David S Lilienthal, M.D. received $667.80 in general payments during 2025 across 26 reported records.
Amgen Inc. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $249.48 | 37.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.84 | 31.6% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.42 | 13.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.35 | 5.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.26 | 5.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.09 | 4.5% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.36 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $667.80 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $249.48 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.42 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.61 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.61 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1116 | 281 |
| Amlodipine Besylate | Amlodipine Besylate | 815 | 211 |
| Pantoprazole Sodium | Pantoprazole Sodium | 782 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 768 | 189 |
| Lisinopril | Lisinopril | 653 | 177 |
| Metformin Hcl | Metformin Hcl | 436 | 123 |
| Escitalopram Oxalate | Escitalopram Oxalate | 389 | 88 |
| Simvastatin | Simvastatin | 341 | 87 |
| Atenolol | Atenolol | 323 | 75 |
| Omeprazole | Omeprazole | 308 | 78 |
| Alprazolam | Alprazolam | 298 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 63 |
| Potassium Chloride | Potassium Chloride | 255 | 74 |
| Clonazepam | Clonazepam | 254 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 254 | 68 |
| Prednisone | Prednisone | 252 | 192 |
| Trazodone Hcl | Trazodone Hcl | 222 | 62 |
| Gabapentin | Gabapentin | 216 | 59 |
| Furosemide | Furosemide | 209 | 53 |
| Montelukast Sodium | Montelukast Sodium | 206 | 60 |
| Losartan Potassium | Losartan Potassium | 204 | 41 |
| Eliquis | Apixaban | 200 | 43 |
| Alendronate Sodium | Alendronate Sodium | 177 | 58 |
| Allopurinol | Allopurinol | 176 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 41 |
| Tramadol Hcl | Tramadol Hcl | 165 | 51 |
| Famotidine | Famotidine | 160 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 44 |
| Synthroid | Levothyroxine Sodium | 156 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 37 |
| Donepezil Hcl | Donepezil Hcl | 127 | 35 |
| Trulicity | Dulaglutide | 127 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 37 |
| Ozempic | Semaglutide | 115 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 20 |
| Carvedilol | Carvedilol | 98 | 22 |
| Sertraline Hcl | Sertraline Hcl | 96 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 41 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 91 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 20 |
| Irbesartan | Irbesartan | 80 | 21 |
| Finasteride | Finasteride | 79 | suppressed |
| Amoxicillin | Amoxicillin | 73 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 17 |
| Lorazepam | Lorazepam | 72 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Meloxicam | Meloxicam | 67 | 29 |
| Clonidine Hcl | Clonidine Hcl | 63 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 14 |
| Lactulose | Lactulose | 60 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 58 | suppressed |
| Azithromycin | Azithromycin | 57 | 53 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 15 |
| Xarelto | Rivaroxaban | 55 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 54 | 49 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Rybelsus | Semaglutide | 35 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 22 |
| Celecoxib | Celecoxib | 33 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Valsartan | Valsartan | 27 | 11 |
| Dutasteride | Dutasteride | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Cefuroxime | Cefuroxime Axetil | 20 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Theo-24 | Theophylline Anhydrous | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $667.80 · 26 records | Amgen Inc. | ABRYSVO, COMIRNATY, CONTRAVE, FREESTYLE LIBRE 3, ONZETRA XSAIL, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error